Holen Sie sich die Stockscreener-App
1.71
0.88%
0.015
Handel nachbörslich:
1.67
-0.04
-2.34%
Schlusskurs vom Vortag:
$1.695
Offen:
$1.73
24-Stunden-Volumen:
130.36K
Relative Volume:
0.69
Marktkapitalisierung:
$61.54M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-0.9048
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+11.04%
1M Leistung:
+16.33%
6M Leistung:
-18.18%
1J Leistung:
+23.91%
1-Tages-Spanne:
$1.63
$1.73
1-Wochen-Bereich:
$1.56
$1.85
52-Wochen-Spanne:
$1.00
$3.83
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
1.71 | 55.42M | 317.00K | -53.47M | -49.31M | -1.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus
Immuneering Corp SEC 10-Q Report - TradingView
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com
What technical indicators reveal about IMRX stock - uspostnews.com
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan
Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World
Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter
Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World
Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks
Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan
Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks
Immuneering Corp SEC 10-K Report - TradingView
Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com
Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan
Immuneering appoints Igor Matushansky as CMO - The Pharma Letter
Immuneering appoints new Chief Medical Officer - Investing.com
Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan
Immuneering Slides As Insider Purchases Lose Another US$186k - Yahoo Finance
Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20 - Armenian Reporter
Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Consensus PT from Analysts - Defense World
Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday - Defense World
Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter
Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - MSN
Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World
Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):